Background/Aims: Monogenic forms of growth hormone insensitivity (GHI) and its treatment with recombinant insulin-like growth factor-1 (rIGF-1) are both associated with glucose dysregulation. We used the information provided by continuous glucose monitoring systems (CGMS) for the clinical management of two children with monogenic GHI prior to the commencement of therapy as well as during the years when they received rIGF-1 treatment and continued to do so after the cessation of therapy. Methods: We evaluated the extent of hyper- and hypoglycaemia with CGMS. Results: In one patient, before treatment CGMS identified self-limiting nocturnal hypoglycaemia. Initiation of rIGF-1 treatment resulted in severe and persistent hypoglycaemia with an absence of spontaneous recovery. Corrective dietary measures were instituted. In a second patient, who had a poor growth response to rIGF-1 therapy, CGMS identified significant fluctuations in daytime glucose levels whilst on treatment with evidence of postprandial hyperglycaemia and both rebound and nocturnal hypoglycaemia. Given the lack of improved growth and the documented glucose dysregulation, treatment was stopped and repeat measurements with CGMS 1 month afterwards showed complete resolution. Conclusions: We have demonstrated that CGMS is an effective tool to assess glucose dysregulation in patients with GHI and alters clinical management.

1.
Laron Z: The essential role of IGF-I: lessons from the long-term study and treatment of children and adults with Laron syndrome. J Clin Endocrinol Metab 1999;84:4397-4404.
2.
Brain CE, Hubbard M, Preece MA, et al: Metabolic status of children with growth hormone insensitivity syndrome and responses to treatment with IGF-I. Horm Res 1998;50:61-70.
3.
Laron Z, Avitzur Y, Klinger B: Carbohydrate metabolism in primary growth hormone resistance (Laron syndrome) before and during insulin-like growth factor-I treatment. Metabolism 1995;44(suppl 4):113-118.
4.
Ranke MB, Savage MO, Chatelain PG, et al: Long-term treatment of growth hormone insensitivity syndrome with IGF-I. Horm Res 1999;51:128-134.
5.
Guler HP, Zapf J, Froesch ER: Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med 1987;317:137-140.
6.
Laron Z, Klinger B, Erster B, et al: Effect of acute administration of insulin-like growth factor I in patients with Laron-type dwarfism. Lancet 1988;2:1170.
7.
Chernausek SD, Backeljauw PF, Frane J, et al: GH insensitivity syndrome collaborative group: long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab 2007;92:902-910.
8.
Laron Z, Klinger B, Jensen LT, et al: Biochemical and hormonal changes induced by one week of administration of rIGF-I to patients with Laron type dwarfism. Clin Endocrinol (Oxf) 1991;35:145-150.
9.
Guler HP, Zapf J, Froesch ER: Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med 1987;317:137-140.
10.
Klinger B, Laron Z: Three year IGF-I treatment of children with Laron syndrome. J Pediatr Endocrinol Metab 1995;8:149-158.
11.
Saif M, Kapoor A, Kochar IP, et al: Continuous glucose monitoring system for congenital hyperinsulinemia. Indian Pediatr 2013;50:421-422.
12.
Chetty VT, Almulla A, Odueyungbo A, et al: The effect of continuous subcutaneous glucose monitoring (CGMS) versus intermittent whole blood finger-stick glucose monitoring (SBGM) on hemoglobin A1c (HBA1c) levels in type I diabetic patients: a systematic review. Diabetes Res Clin Pract 2008;81:79-87.
13.
Davey RJ, Low C, Jones TW, et al: Contribution of an intrinsic lag of continuous glucose monitoring systems to differences in measured and actual glucose concentrations changing at variable rates in vitro. J Diabetes Sci Technol 2010;4:1393-1399.
14.
Bay C, Kristensen PL, Pedersen-Bjergaard U, et al: Nocturnal continuous glucose monitoring: accuracy and reliability of hypoglycemia detection in patients with type 1 diabetes at high risk of severe hypoglycemia. Diabetes Technol Ther 2013;15:371-377.
15.
Zijlstra E, Heise T, Nosek L, et al: Continuous glucose monitoring: quality of hypoglycaemia detection. Diabetes Obes Metab 2013;15:130-135.
16.
Berg MA, Argente J, Chernausek S, et al: Diverse growth hormone receptor gene mutation in Laron syndrome. Am J Hum Genet 1993;52:998-1005.
17.
Recombinant IGF1 Therapy in Children with Severe Primary IGF-1 Deficiency (SPIGFD). Formulated by the UK IGF-1 User's Group. https://www.bsped.org.uk/clinical/docs/UK_IGF1_Guidance_042012.pdf.
18.
Cotterill AM, Holly JMP, Taylor AM, et al: The insulin-like growth factor (IGF-I) binding proteins and IGF bio-activity in Laron-type dwarfism. J Clin Endocrinol Metab 1992;74:56-63.
19.
Siddle K: Signalling by insulin and IGF receptors: supporting acts and new players. J Mol Endocrinol 2011;47:R1-R10.
20.
Savage MO, Blum WF, Ranke MB, et al: Clinical features and endocrine status in patients with growth hormone insensitivity (Laron syndrome). J Clin Endocrinol Metab 1993;77:1465-1471.
21.
Di Cola G, Cool MH, Accili D: Hypoglycemic effect of insulin-like growth factor-1 in mice lacking insulin receptors. J Clin Invest 1997;99:2538-2544.
22.
Unger RH, Orci L: Paracrinology of islets and the paracrinopathy of diabetes. Proc Natl Acad Sci U S A 2010;107:16009-16012.
23.
Herzog RI, Sherwin RS, Rothman DL: Insulin-induced hypoglycemia and its effect on the brain: unraveling metabolism by in vivo nuclear magnetic resonance. Diabetes 2011;60:1856-1858.
24.
McCrimmon RJ, Ryan CM, Frier BM: Diabetes and cognitive dysfunction. Lancet 2012;379:2291-2299.
25.
Agladıoglu SY, Cetınkaya S, Erdeve SS, et al: Diabetes mellitus with Laron syndrome: case report. J Pediatr Endocrinol Metab 2013;26:955-958.
26.
Latrech H, Simon A, Beltrand J, et al: Postprandial hyperglycemia corrected by IGF-I (Increlex®) in Laron syndrome. Horm Res Paediatr 2012;78:193-200.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.